Literature DB >> 20963600

Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity.

Tamás Karosi1, Péter Csomor, Anita Szalmás, József Kónya, Mihály Petkó, István Sziklai.   

Abstract

Otosclerosis is a complex bone dystrophy of the human otic capsule leading to conductive and sensorineural hearing loss. Since otosclerosis may, at least in part, be considered as an autoimmune-inflammatory disease, disturbed balance of TNF-alpha and osteoprotegerin (OPG) expression has been implicated in the pathological bone remodeling. It has been supposed that active otosclerosis is characterized by decreased or missing local OPG production with invariable OPG sensitivity of the otosclerotic foci. Ankylotic stapes footplates (n = 41) removed by stapedectomy were processed to histological examination, OPG-specific RT-PCR, tissue culturing and alkaline-phosphatase (AP) activity assessment, respectively. OPG concentration of serum specimens (n = 41) was measured by ELISA. Cortical bone fragments harvested from the external ear canal were used as negative controls of otosclerosis. Among 41 ankylotic stapes footplates, 22 active and 19 inactive otosclerosis cases were histologically diagnosed. OPG expression was significantly lower (p < 0.001) in active otosclerosis compared to inactive cases. Osteoclast cultures originated from active otosclerotic foci showed a considerable susceptibility against external OPG dosage, which resulted in a significant decrease of AP activity (p < 0.001). In contrast, OPG serum levels were in the normal range (5-100 ng/ml) indicating a non-systemic bone resorption. In conclusion, secondary decreased local OPG production might play an important role in the pathogenesis of otosclerotic bone remodeling disorder. As to previous and current results, decreased OPG sensitivity of lesion-forming cells should be excluded. These observations may indicate the potential role of recombinant OPG treatment in early stages of otosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963600     DOI: 10.1007/s00405-010-1404-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  30 in total

1.  Codetection of measles virus and tumor necrosis factor-alpha mRNA in otosclerotic stapes footplates.

Authors:  Tamás Karosi; József Kónya; László Z Szabó; József Pytel; József Jóri; Anita Szalmás; István Sziklai
Journal:  Laryngoscope       Date:  2005-07       Impact factor: 3.325

2.  Predilection of otosclerotic foci related to the bone turnover in the otic capsule.

Authors:  T Frisch; M S Sørensen; S Overgaard; P Bretlau
Journal:  Acta Otolaryngol Suppl       Date:  2000

3.  Differences in gene expression between the otic capsule and other bones.

Authors:  Konstantina M Stankovic; Osamu Adachi; Kunikazu Tsuji; Arthur G Kristiansen; Joe C Adams; Vicki Rosen; Michael J McKenna
Journal:  Hear Res       Date:  2010-02-08       Impact factor: 3.208

4.  Medicine-based evidence: reverse translational ear research recommendations.

Authors:  Kenneth H Brookler
Journal:  Int Tinnitus J       Date:  2009

5.  Ultrastructural and immunohistochemical evidence of measles virus in active otosclerosis.

Authors:  M J McKenna; B G Mills
Journal:  Acta Otolaryngol Suppl       Date:  1990

6.  The spatial distribution of otosclerosis: a quantitative study using design-based stereology.

Authors:  Sune Land Bloch; Mads Sølvsten Sørensen
Journal:  Acta Otolaryngol       Date:  2010-05       Impact factor: 1.494

7.  Three-dimensional reconstruction of the otosclerotic focus.

Authors:  Sune Land Bloch; Mads Sølvsten Sørensen
Journal:  Acta Otolaryngol       Date:  2010-04       Impact factor: 1.494

8.  Otosclerosis: an organ-specific inflammatory disease with sensorineural hearing loss.

Authors:  István Sziklai; Tamás József Batta; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-02       Impact factor: 2.503

Review 9.  The effect of sex hormones on bone metabolism of the otic capsule--an overview.

Authors:  Kathleen C Horner
Journal:  Hear Res       Date:  2008-12-24       Impact factor: 3.208

10.  Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene.

Authors:  Kiyoshi Nakatsuka; Yoshiki Nishizawa; Stuart H Ralston
Journal:  J Bone Miner Res       Date:  2003-08       Impact factor: 6.741

View more
  5 in total

1.  Computed Tomography Density as a Bio-marker for Histologic Grade of Otosclerosis: A Human Temporal Bone Pathology Study.

Authors:  Alicia M Quesnel; Reuven Ishai; Timothy Meehan; Jennifer T O'Malley; Renee Mitchell; Jennifer J Shin; Hugh D Curtin; Joseph B Nadol; Michael J McKenna; Amy F Juliano
Journal:  Otol Neurotol       Date:  2022-07-01       Impact factor: 2.619

Review 2.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

3.  Exclusion of TNFRSF11B as Candidate Gene for Otosclerosis in Campania Population.

Authors:  Sandra Iossa; Giovanna Morello; Teresa Esposito; Virginia Corvino; Pasquale Giannini; Raffaella Salvato; Michele Cavaliere; Maria Panetti; Giuseppe Panetti; Bruno Piantedosi; Fernando Gianfrancesco; Elio Marciano; Annamaria Franzè
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-01-30

4.  Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss.

Authors:  Shyan-Yuan Kao; Judith S Kempfle; Jane B Jensen; Deborah Perez-Fernandez; Andrew C Lysaght; Albert S Edge; Konstantina M Stankovic
Journal:  Neurobiol Dis       Date:  2013-04-20       Impact factor: 5.996

5.  Expression of TNF-α, OPG, IL-1β and the presence of the measles virus RNA in the stapes of the patients with otosclerosis.

Authors:  Małgorzata Potocka-Bakłażec; Monika Sakowicz-Burkiewicz; Jerzy Kuczkowski; Tadeusz Pawełczyk; Czesław Stankiewicz; Wojciech Sierszeń; Zbigniew Jankowski; Jacek Buczny
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-28       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.